

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  39D2220431	<b>(X3) Date Survey Completed</b>  09/22/2021
<b>Name of Provider or Supplier</b>  Pa Dermatology Partners - King Of Prussia	<b>Street Address, City, State</b>  200 Mall Blvd, King Of Prussia, PA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D5601</b>	<p>HISTOPATHOLOGY CFR(s): 493.1273(a)(f)</p> <p>(a) As specified in 493.1256(e)(3), fluorescent and immunohistochemical stains must be checked for positive and negative reactivity each time of use. For all other differential or special stains, a control slide of known reactivity must be stained with each patient slide or group of patient slides. Reactions of the control slide with each special stain must be documented. (f) The laboratory must document all control procedures performed, as specified in this section.</p> <p>This STANDARD is not met as evidenced by: Based on a review of quality control (QC) records and interview with Chief Operating Officer (COO), the laboratory did not document Hematoxylin and Eosin (H &amp; E) stain QC monitoring activities for intended reactivity from 06/01/2021 to the day of survey. Findings include: 1. On day of survey 09/22/2021 at 09:55 a.m., The laboratory could not provide QC documentation for staining characteristics for the H&amp;E stain performed from 6/1/2021 to 09/22/2021 2. The COO confirmed the finding above on 09/22/2021 at 10:15 a.m.</p>